Recognising the value in value added medicines is key to our vision of transforming the future of healthcare. With this in mind, we are pleased to announce that we’ve been accepted as a member of the Medicines for Europe Value Added Medicines Group. This group represents a collection of industry leaders, who are all dedicated to making healthcare accessible through high-quality, affordable medicines.
Andy Trouton, Managing Director of Colonis Pharma Ltd commented: “We share Medicines for Europe’s commitment to enhancing patient care by addressing unmet needs with value added medicines. Our innovative approach aligns perfectly with the values of Medicines for Europe, as we continue to champion better healthcare solutions for all.”
Adrian van den Hoven, Director General of Medicines for Europe, said: “We are delighted to have Colonis join us as a member of the Value Added Medicines Group. We look forward to their support as we strive to build a robust framework for value added medicines development and give patients better accessibility to the healthcare they need.”
GB-CPL-0-198
October 2024
